Core Viewpoint - The chemical new materials industry is expected to enter a rapid growth phase driven by policy support, industrial transformation, and increasing domestic demand for high-performance materials in sectors such as semiconductors, electronics, and renewable energy [2][11][12]. Group 1: Industry Growth and Market Potential - The global chemical new materials market was valued at approximately $370 billion in 2019 and is projected to reach $480 billion by 2025, with a CAGR of about 4.4% [3][16]. - The domestic market for chemical new materials is estimated to grow from approximately 900 billion yuan in 2019 to 1.5 trillion yuan by 2025, reflecting a CAGR of 8.6% [3][25]. - The demand for chemical new materials is expected to continue growing due to the transformation and upgrading of industries such as semiconductors, electronics, and renewable energy [3][25]. Group 2: Policy Support and Technological Advancements - The Chinese government has increased support for high-end manufacturing and new materials since the US-China trade tensions began in 2018, with policies aimed at promoting self-sufficiency in the supply chain [2][12]. - The Ministry of Industry and Information Technology released a directory in December 2021 that includes over 300 types of new materials, highlighting the government's commitment to advancing this sector [4][12]. - Domestic companies have significantly increased their R&D investments, with a reported 17 billion euros in 2019, reflecting a CAGR of 36% from 2014 to 2019 [4][27]. Group 3: Domestic Industry Landscape - The domestic chemical new materials industry has a strong foundation, with a market value of approximately 600 billion yuan in 2019, but still relies heavily on imports for high-end products [17]. - Key domestic players such as Wanhua Chemical, Hualu Hengsheng, and Jinhai Technology are making strides in the new materials sector through innovation and technology adoption [33]. - The industry is characterized by a significant opportunity for domestic substitution, particularly in high-end polyolefins, engineering plastics, and functional films, where self-sufficiency remains low [17][19]. Group 4: Emerging Opportunities and Trends - The demand for high-performance fibers, films, and electronic chemicals is expected to grow rapidly, driven by advancements in sectors like renewable energy and electronics [5][25]. - Emerging materials such as aerogels and biobased materials are gaining traction, with domestic companies positioned to capture early market share in these innovative fields [5][19]. - The lifecycle of many new materials in China is still in the early stages, indicating substantial room for growth and development compared to more mature markets in developed countries [19][20].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-028 上海凯赛生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/22 ， 由 原 控 | | 公 | 司 | | 股 | 股 | 东 | Cathay | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Industrial Biotech Ltd.提议 | | | | | | | | | | 回购方案实施期限 | 2024 年 月 21 日~2025 年 | 10 | | | 10 | 月 | 20 | 日 | | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | | □ ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-031 上海凯赛生物技术股份有限公司 续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日 召开第二届董事会第三十二次会议，审议通过了《关于续聘 2025 年度审计机构 的议案》，公司拟继续聘任天健会计师事务所（特殊普通合伙）（以下简称"天健"） 为公司 2025 年度财务及内部控制审计机构，该议案尚需提请公司 2024 年年度股 东大会审议。现将相关事宜公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | --- | --- | --- | | 成立日期 | 2011 年 7 月 18 日 | 组织形式 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区西溪路 | 128 号 6 楼 | | 首席合 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-030 上海凯赛生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 27 日 至2025 年 6 月 27 日 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 6 月 27 日 14 点 00 分 召开地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688065 证券简称：凯赛生物 公告编号：2025-029 上海凯赛生物技术股份有限公司 第二届监事会第二十六次会议决议公告 表决结果：3票同意；0票反对；0票弃权。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关于 续聘会计师事务所的公告》（公告编号：2025-031）。 特此公告。 上海凯赛生物技术股份有限公司 监 事 会 2025 年 6 月 5 日 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 5 月 25 日向全 体监事以邮件方式发出会议通知，并于 2025 年 6 月 4 日 15:00 以通讯会议的方式召 开第二届监事会第二十六次会议。本次会议由监事会主席张国华主持，会议应到 3 人， 实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规 章、规范性文件和《公司章程》的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 审议通过《关于续 ...

Core Viewpoint - The new materials industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation, with a projected total output value of 8.48 trillion yuan in 2024, maintaining double-digit growth for 14 consecutive years [1][3][20]. Group 1: Industry Definition and Classification - New materials refer to recently developed or developing structural and functional materials with superior properties. They can be classified into structural materials and functional materials based on their usage, and further categorized into four types: metal materials, inorganic non-metal materials, organic polymer materials, and advanced composite materials [1]. Group 2: Current Development Status - The new materials industry has expanded significantly, with the government focusing on electronic information materials, aerospace materials, new energy materials, and environmentally friendly materials. National high-tech industrial bases for new materials have been established in seven cities [3][5]. Group 3: Market Size and Structure - In 2024, the chemical new materials market is expected to account for approximately 22.08% of the total new materials market in China, while battery new materials will represent about 6.66%. By 2025, these figures are projected to be 21.75% and 6.97%, respectively [7]. Group 4: Competitive Landscape - Major companies in the new materials sector include Lens Technology, Antai Technology, China National Materials, and others, which are enhancing their international competitiveness through technological innovation and market expansion [12][16]. Group 5: Development Trends - The demand for new materials is increasing due to the rapid development of downstream industries such as information technology and new energy. The industry is transitioning towards low-carbon and green development, supported by significant technological advancements [20][23].

Core Viewpoint - The article discusses the ongoing projects and strategic developments of Kaisa Bio, highlighting the delays in their major production projects and the establishment of new production bases in response to market demands and infrastructure changes [1][3][4]. Group 1: Project Developments - Kaisa Bio's project in the Shanxi Synthetic Biology Industrial Park is experiencing delays due to changes in infrastructure planning, affecting the annual production of 900,000 tons of bio-based polyamide [1][3]. - The company has completed a production line capable of producing 5,000 tons of bio-based high-temperature polyamide, which meets current demands for continuous fiber composite materials [1][2]. - The total investment for the Shanxi project is planned at 80 billion yuan, with the first phase involving 45 billion yuan and the second phase 35 billion yuan, aiming for a total output value exceeding 100 billion yuan upon completion [2]. Group 2: Strategic Partnerships - In May 2024, Kaisa Bio signed a strategic cooperation agreement with the Hefei municipal government and China Merchants Group to establish a joint venture focused on bio-based polyamide composite materials [4]. - The Hefei project aims to create an industrial ecosystem for bio-based materials, with the establishment of a company for research, production, and sales of bio-based polyamide composites [4]. - The collaboration is expected to enhance the development of a complete industrial chain for bio-based materials, positioning Kaisa Bio as a key player in the bio-based materials market [4].

Core Viewpoint - The article discusses the establishment and investment plans of招商凯赛生物材料 (Zhongshan Kaisa Biochemical Materials) in the production of bio-based composite materials, highlighting its commitment to green and sustainable manufacturing practices. Group 1: Project Overview - 招商凯赛生物材料 plans to invest 468.5 million yuan in an annual production project of 41,000 tons of bio-based composite materials, which includes 20,000 tons/year of composite products, 3,000 tons/year of photovoltaic frame products, and 18,000 tons/year of construction template products. The project is scheduled to be built from April 2025 to December 2026 [1]. - The bio-based polyamide is produced from renewable biomass resources, utilizing biological, chemical, and physical methods to create monomers for synthetic polyamide, resulting in a polymer material that is green, environmentally friendly, and renewable [1]. Group 2: Company Background - 招商凯赛生物材料 was established in December 2024, funded by Shanghai Kaisa Biotechnology Co., Ltd. The company focuses on the research and production of bio-based polyamide resins for composite product processing, emphasizing the green, low-carbon, and energy-saving characteristics of its products [2]. - The company has been actively developing new materials such as bio-based long-chain polyamides and high-temperature polyamides, while also promoting innovative projects like continuous fiber-reinforced bio-based polyamide composites and the utilization of agricultural waste [2]. Group 3: Collaboration and Future Plans - In May 2024, Hefei City signed a tripartite cooperation agreement with 招商创科 and 凯赛生物 to advance the development of the bio-manufacturing industry, with a total investment of approximately 5 billion yuan planned for the project in two phases [2]. - The first phase involves an investment of 1 billion yuan, which includes the composite project and bio-based polyamide modification project, while the second phase plans to invest 4 billion yuan, focusing on further capacity expansion and collaborations with companies like 宁德时代 and 韩国3P公司 [2].

Core Insights - Synthetic biology is at a pivotal growth point in China, attracting significant attention from global investors due to its unique innovation potential and broad application prospects [1] - The Chinese synthetic biology market comprises 116 listed companies, including technology platform providers, CXO companies offering biosynthesis solutions, and chemical and pharmaceutical companies seeking transformation [1] - The industry showcases a mix of established players with decades of experience and newly founded companies, highlighting the vast development potential and imagination space behind synthetic biology [1] Industry Overview - Enabling technology companies in synthetic biology are experiencing rapid growth, leveraging cutting-edge technologies such as gene editing, gene synthesis, gene sequencing, big data, and machine learning [1] - Current enabling technologies are still in their early stages, with high technical barriers, leading companies to pursue collaborations with universities, research institutions, and other enterprises to advance R&D [1] Leading Companies - BGI Genomics and Berry Genomics are recognized as leaders among enabling technology companies in China's synthetic biology sector [2] - BGI Genomics focuses on gene sequencing instruments, laboratory automation, and new business areas, enhancing its global influence in precision medicine and health [3] - Berry Genomics, a leader in gene sequencing, offers services in reproductive health, genetic disease detection, and tumor detection, supported by proprietary technologies like PCR-free methods [6] Platform Companies - Synthetic biology platform companies primarily provide services related to process improvement and enzyme engineering, with few achieving the functionality of cell factories [9] - Kingfisher Biotech is a prominent global gene supplier, evolving into a leading provider of research and production services with a strong reputation in life sciences [11] - Yikole Biotech specializes in synthetic biology technology, focusing on biomanufacturing and possessing a vast library of over 20,000 enzymes [13][16] Emerging Trends - The Chinese synthetic biology sector is witnessing a surge in investment opportunities driven by policy guidance and market demand, with companies increasing their focus on technological innovation and R&D [22] - Key application areas include biopharmaceutical raw materials, bio-based materials, and the development of cell and gene therapy drugs, supported by integrated R&D and production capabilities [16][20]

（一） 股东大会召开的时间：2025 年 5 月 16 日 证券代码：688065 证券简称：凯赛生物 公告编号：2025-027 上海凯赛生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例（%） | 票数 | 比例（%） | | 普通股 | 480,100,167 | 99.9685 | 148,524 | 0.0309 | 2,700 | 0.0006 | （二） 股东大会召开的地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 156 | | --- ...